Literature DB >> 10683120

Rosiglitazone approved for treatment of type 2 diabetes.

J L Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10683120     DOI： 10.1093/ajhp/56.13.1292

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN： 1079-2082            Impact factor:   2.637


× No keyword cloud information.
  4 in total

1.  Effect of ligand of peroxisome proliferator-activated receptor gamma on the biological characters of hepatic stellate cells.

Authors:  Yan-Tong Guo; Xi-Sheng Leng; Tao Li; Ji-Run Peng; Sheng-Han Song; Liang-Fa Xiong; Zhi-Zhong Qin
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

Review 2.  Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  Antona J Wagstaff; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Differential sensitivities of the vascular K(ATP) channel to various PPAR activators.

Authors:  Yingji Wang; Lei Yu; Ningren Cui; Xin Jin; Daling Zhu; Chun Jiang
Journal:  Biochem Pharmacol       Date:  2013-03-13       Impact factor: 5.858

Review 4.  PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases.

Authors:  Márcia V de Carvalho; Cassiano F Gonçalves-de-Albuquerque; Adriana R Silva
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.